Measuring the value of health-related quality of life

Quality of Life Impairment in Schizophrenia, Mood and Anxiety Disorders: New Perspectives on Research and Treatment

Volumn , Issue , 2007, Pages 99-132

  Hawthorne, Graeme ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

15D; AQoL; Burden of disease; Cost effectiveness; Cost utility analysis; CUA; Economic evaluation; EQ5D; Health related quality of life; HUI3; Multi attribute utility instrument; QALY; Quality adjusted life years; QWB; Rosser Index; SF6D

Indexed keywords

EID: 79451473518     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-5779-3_6     Document Type: Chapter

References (162)

1. Ostenfeld E. Aristotle on the good life and quality of life. In: Nordenfelt L, editor. Concepts and Measurement of Quality of Life in Health Care. Dordrecht: Kluwer Academic Publishers; 1994. p. 19-34.
2. Long PH. On the quantity and quality of life. Med. Times 1960;88:613-9.
3. Elkinton JR. Medicine and the quality of life. Ann. Intern. Med. 1966;64(3):711-4.
4. Imhof A. The implications of increased life expectancy for family and social life. In: Wear A, editor. Medicine in Society: Historical Essays. Cambridge: Cambridge University Press; 1992.
5. Nordenfelt L, editor. Concepts and Measurement of Quality of Life in Health Care. Dordrecht: Kluwer Academic; 1994.
6. Walker S, Rosser R. Quality of life assessment: key issues in the 1990s. Dordrecht: Kluwer Academic Publishers; 1993.
7. Williams B. Patient satisfaction: a valid concept? Soc. Sci. Med. 1994;38(4):509-516.
8. Sitzia J, Wood N. Patient satisfaction: a review of issues and concepts. Soc. Sci. Med. 1997;45(12):1829-1843.
9. Bowling A. Measuring Health: A Review of Quality of Life Measurement Scales. Milton Keynes: Open University; 1991.
10. Drummond M, O'Brien B, Stoddart G, et al. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford: Oxford University Press; 1998.
11. Productivity Commission. Economic Implications of an Ageing Australia. Canberra: Commonwealth of Australia; 2005.
12. Productivity Commission. Impacts of Medical Technology in Australia. Melbourne: Productivity Commission; 2005.
13. Mathers C, Vos T, Stevenson C. The Burden of Disease and Injury in Australia. Canberra: Australian Institute of Health and Welfare; 1999.
14. Suchman EA. Evaluative Research: Principles and Practice in Public Service & Social Action Programs. New York: Russell Sage Foundation; 1967.
15. Foucault M. Madness and civilization; a history of insanity in the Age of Reason. New York: Vintage Books; 1965.
16. WHOQoL Group. Study protocol for the World Health Organization project to develop a quality of life assessment instrument (WHOQOL). Qual. Life Res. 1993;2:153-159.
17. Atkinson M, Zibin S, Chuang H. Characterizing quality of life among patients with chronic mental illness: a critical examination of the self-report methodology. Am. J. Psychiatry 1997;154:99-105.
18. Awad G, Voruganti P. Cost-utility analysis in schizophrenia. J. Clin. Psychiatry 1999;60(Suppl 3): 22-28.
19. Voruganti L, Heslegrave R, Awad A, et al. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol. Med. 1998;28: 165-172.
20. Herrman H, Hawthorne G, Thomas R. Quality of life assessment in people living with psychosis. Soc. Psychiatry Psychiatr. Epidemiol. 2002;37(11):510-518.
21. Sackett D, Torrance G. The utility of different health states as perceived by the general public. J. Chronic Dis. 1978;31:697-704.
22. Torrance G, Boyle M, Horwood S. Application of multi-attribute theory to measure social preferences for health states. Oper. Res. 1982;30:1043-1069.
23. Patrick DL, Bush JW, Chen MM. Toward an operational definition of health. J. Health Soc. Behav. 1973;14(1):6-23.
24. Rosser R, Kind P. A scale of valuations of states of illness: is there a social consensus. Int. J. Epidemiol. 1978;7(4):347-58.
25. Ubel PA, Richardson J, Menzel P. Societal value, the person trade-off, and the dilemma of whose values to measure for cost-effectiveness analysis. Health Econ. 2000;9(2):127-36.
26. Ubel PA, Loewenstein G, Jepson C. Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Qual. Life Res. 2003;12:599-607.
27. Shortell R, Richardson W. Health Program Evaluation. St Louis: Mosby; 1978.
28. Ovretveit J. Evaluating Health Interventions. Buckingham: Open University Press; 1998.
29. Singh B, Hawthorne G, Vos T. The role of economic evaluation in mental health care. Aust. N. Z. J. Psychiatry 2001;35:104-117.
30. Torrance G. Measurement of health state utilities for economic appraisal: a review. J. Health Econ. 1986;5:1-30.
31. Hawthorne G, Richardson J, Day N, et al. Life and Death: Theoretical and Practical Issues in Utility Measurement. Melbourne: Centre for Health Program Evaluation; 2000. Working Paper 102.
32. Richardson J, Hawthorne G. Negative Utilities and the Evaluation of Complex Health States: Issues Arising from the Scaling of a Multiattribute Utility Instrument. Melbourne: Centre for Health Program Evaluation; 2000. Working Paper 113.
33. Richardson J. Cost utility analysis: what should be measured? Soc. Sci. Med. 1994;39(1):7-21.
34. Brazier J, Deverill M, Green C, et al. A review of the use of health status measures in economic evaluation. Health Technol. Assess. 1999;3(9):1-165.
35. Bennett K, Torrance G. Measuring health state preferences and utilities: rating scale, time tradeoff, and standard gamble techniques. In: Spilker B, editor. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven Publishers; 1996. p. 253-265.
36. Robinson A, Dolan P, Williams A. Valuing health states using VAS and TTO: what lies behind the numbers? Soc. Sci. Med. 1997;45(8):1289-1297.
37. Gudex C, Kind P, van Dalen H, et al. Comparing Scaling Methods for Health State Valuations-Rosser Revisited. Discussion Paper. York: Centre for Health Economics, University of York; 1993. Report No.: 107.
38. Rosser R. A health index and output measure. In: Walker S, Rosser R, editors. Quality of Life Assessment: Key Issues in the 1990s. Dordrecht: Kluwer Academic Publishers; 1993.
39. von Winterfeldt D, Edwards W. Decision Analysis and Behavioural Research. Cambridge: Cambridge University Press; 1986.
40. Hawthorne G, Richardson J, Osborne R. The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health related quality of life. Qual. Life Res. 1999;8:209-224.
41. Hawthorne G, Richardson J, Day N. A comparison of the Assessment of Quality of Life (AQoL) with four other generic utility instruments. Ann. Med. 2001;33(5):358-370.
42. Hawthorne G, Richardson J, Day N, et al. Construction and Utility Scaling of the Assessment of Quality of Life (AQoL) Instrument. Melbourne: Centre for Health Program Evaluation; 2000. Working Paper 101.
43. EuroQol Group. EuroQol: a new facility for measurement of health-related quality of life. Health Policy 1990;16:199-208.
44. Kind P. The EuroQoL instrument: an index of health-related quality of life. In: Spilker B, editor. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelpha: Lippincott-Raven Publishers; 1996. p. 191-201.
45. Feeny D, Furlong W, Torrance G. Health Utilities Index Mark 2 and Mark 3 (HUI2/3) 15-item questionnaire for self-administered, self-assessed usual health status. Hamilton: Centre for Health Economics and Policy Analysis, McMaster University; 1996.
46. Feeny D, Torrance G, Furlong W. Health utilities index. In: Spilker B, editor. Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd ed. Philadelpha: Lippincott-Raven Publishers; 1996.
47. Torrance GW, Furlong W, Feeny D, et al. Multi-attribute preference functions. Health Utilities Index. Pharmacoeconomics 1995;7(6):503-20.
48. Sintonen H, Pekurinen M. A fifteen-dimensional measure of health-related quality of life (15D) and its applications. In: Walker S, Rosser R, editors. Quality of Life Assessment. Dordrecht: Kluwer Academic Publishers; 1993.
49. Sintonen H. The 15D measure of health-related quality of life: feasibility, reliability and validity of its valuation system. Melbourne: National Centre for Health Program Evaluation; 1995. Working Paper 42.
50. Sintonen H. The 15D measure of health-related quality of life: reliability, validity and sensitivity of its health state descriptive system. Melbourne: National Centre for Health Program Evaluation; 1994. Working Paper 41.
51. Kaplan R, Anderson J, Ganiats T. The Quality of Well-Being Scale: rationale for a single quality of life index. In: Walker S, Rosser R, editors. Quality of Life Assessment: Key Issues in the 1990s. Dordrecht: Kluwer Academic Publishers; 1993.
52. Kaplan RM, Alcaraz JE, Anderson JP, et al. Quality-adjusted life years lost to arthritis: effects of gender, race, and social class. Arthritis Care Res. 1996;9(6):473-82.
53. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J. Health Econ. 2002;21:271-292.
54. Brazier J, Usherwood T, Harper R, et al. Deriving a preference-based single index from the UK SF-36 Health Survey. J. Clin. Epidemiol. 1998;51(11):1115-1128.
55. Hawthorne G, Richardson J. An Australian MAU/QALY Instrument: Rationale and Preliminary Results. In: Sansoni J, editor. Proceedings Health Outcomes and Quality of Life Measurement Conference; 1995; Canberra: The Australian Health Outcomes Collaboration. The University of Wollongong; 1995.
56. Nord E. A Review of Synthetic Health Indicators. Oslo: National Institute of Public Health for the OECD Directorate for Education, Employment, Labour and Social Affairs; 1997.
57. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann. Med. 2001;33:337-343.
58. Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv. Res. 1988;23(2):203-35.
59. Bergner M, Bobbitt RA, Carter WB, et al. The Sickness Impact Profile: development and final revision of a health status measure. Med. Care 1981;19(8):787-805.
60. Hunt S, McKenna S, McEwen J, et al. The Nottingham Health Profile: subjective health status and medical consultations. Soc. Sci. Med. 1981;15A:221-229.
61. Dolan P. Modeling valuations for EuroQol health states. Med. Care 1997;35(11):1095-1108.
62. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med. Care 2005;43(3):203-20.
63. Havranek EP, Steiner JF. Valuation of health states in the US versus the UK: two measures divided by a common language? Med. Care 2005;43(3):201-2.
64. Johnson JA, Luo N, Shaw JW, et al. Valuations of EQ-5D health states: are the United States and United Kingdom different? Med. Care 2005;43(3):221-8.
65. Fryback DG. A US valuation of the EQ-5D. Med. Care 2005;43(3):199-200
66. MVHGroup. The Measurement and Valuation of Health: Final Modelling of Valuation Tariffs. York: Centre for Health Economics; 1995.
67. Dolan P, Gudex C, Kind P, et al. Valuing health states: a comparison of methods. J. Health Econ. 1996;15:209-231.
68. Furlong WJ, Feeny DH, Torrance GW, et al. The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies. Ann. Med. 2001;33:375-384.
69. Furlong W, Feeny D, Torrance G, et al. Multiplicative Multi-attributeUtilityFunctionfortheHealth Utilities Index Mark 3 (HUI3) System: A Technical Report. Working Paper. Hamilton: McMaster University, Centre for Health Economics and Policy Analysis; 1998. Report No.: 98-11.
70. Sintonen H. The 15D instrument of health-related quality of life: properties and applications. Ann. Med. 2001;33:328-336.
71. McDowell I, Newell C, editors. Measuring health: a guide to rating scales and questionnaires. New York: Oxford University Press; 1987.
72. Cadet B. History of the construction of a health indicator integrating social preference: the Quality of Well-Being Scale. In: 7th Meeting, International Network on Health Expectancy (REVES); 1994 23-25 February; Canberra; 1994.
73. Kaplan R, Bush J, Berry C. Health status: types of validity and the Index of Well-being. Health Serv. Res. 1976;11(4):478-507.
74. Anderson J, Kaplan R, Berry C, et al. Interday reliability of function assessment for a health status measure: The Quality of Well-Being scale. Med. Care 1989;27(11):1076-1084.
75. Kaplan R, Ganiats T, Sieber W, et al. The Quality of Well-being Scale. Medical Outcomes Trust Bulletin 1996:2-3.
76. Bombardier C, Raboud J. A comparison of health-related quality-of-life measures for rheumatoid arthritis research. The Auranofin Cooperating Group. Control. Clin. Trials 1991;12(4 Suppl): 243S-256S.
77. Coons S, Kaplan R. Quality of life assessment: understanding its use as an outcome measure. Hosp. Formul. 1993;28:486-498.
78. Kind P, Gudex C. Measuring health status in the community: a comparison of methods. J. Epidemiol. Community Health 1994;48:86-91.
79. Martin A, Glasziou P, Simes R. A Utility-Based Quality of Life Questionnaire for Cardiovascular Patients: Reliability and Validity of the UBQ-H(eart) Items. Sydney: NHMRC Clinical Trials Centre, University of Sydney; 1996.
80. Hawthorne G, Richardson J. Measuring the value of program outcomes: a review of utility measures. Exp. Rev. Pharm. Outcomes Res. 2001;1(2):215-228.
81. Barton GR, Bankart J, Davis AC, et al. Comparing utility scores before and after hearing-aid provision: results according to the EQ-5D, HUI3 and SF-6D. Appl. Health Econ. Health Policy 2004;3(2):103-5.
82. Barton GR, Bankart J, Davis AC. A comparison of the quality of life of hearing-impaired people as estimated by three different utility measures. Int. J. Audiol. 2005;44(3):157-63.
83. Conner-Spady B, Suarez-Almazor ME. Variation in the estimation of quality-adjusted life-years by different preference-based instruments. Med. Care 2003;41(7):791-801.
84. Hawthorne G, Richardson J, Day N. A comparison of five multi-attribute utility instruments.Aust. Stud. Health Serv Admin 2001;89: 151-179.
85. Kopec JA, Willison KD. A comparative review of four preference-weighted measures of health-related quality of life. J. Clin. Epidemiol. 2003;56(4):317-25.
86. Marra CA, Woolcott JC, Kopec JA, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc. Sci. Med. 2005;60(7):1571-82.
87. Pickard AS, Johnson JA, Feeny DH. Responsiveness of generic health-related quality of life measures in stroke. Qual. Life Res. 2005;14(1):207-19.
88. Robinson A, Loomes G, Jones-Lee M. Visual analog scales, standard gambles and relative risk aversion. Med. Decis. Making 2001;21(1):17-27.
89. Torrance GW, Feeny D, Furlong W. Visual analog scales: do they have a role in the measurement of preferences for health states? Med. Decis. Making 2001;21(4):329-34.
90. Dolan P, Gudex C, Kind P, et al. Social tariff for EUROQoL: results from a UK general population survey. York: Centre for Health Economics, University of York; 1995. Discussion Paper 138.
91. Bleichrodt H, Johannesson M. An experimental test of a theoretical foundation for rating-scale valuations. Med. Decis. Making 1997;17(2):208-16.
92. Nord E. Unjustified use of the Quality of Well-Being Scale in priority setting in Oregon. Health Policy 1993;24(1):45-53.
93. Hollingworth W, Mackenzie R, Todd CJ, et al. Measuring changes in quality of life following magnetic resonance imaging of the knee: SF-36, EuroQol or Rosser index? Qual. Life Res. 1995;4(4):325-34.
94. Nord E, Richardson J, Macarounas-Kirchmann K. Social evaluation of health care versus personal evaluation of health states. Evidence on the validity of four health-state scaling instruments using Norwegian and Australian surveys. Int. J. Technol. Assess. Health Care 1993;9(4):463-78.
95. Mulkay M, Ashmore M, Pinch T. Measuring the quality of life: a sociological intervention concerning the application of economics to health care. Sociology 1987;21:541-564.
96. Elvik R. The validity of using health state indexes in measuring the consequences of traffic injury for public health. Soc. Sci. Med. 1995;40(10):1385-98.
97. DeptHealth. Research Group on the measurement and valuation of health. In: Methodology Workshop, EUROQoL Conference; 1995; London: Economics & Operational Research Division, Department of Health; 1995.
98. Richardson C, Zumbo B. A statistical examination of the Health Utility Index-Mark III as a summary measure of health status for a general population survey. Soc. Ind. Res. 2000;51(2):171-191.
99. Cattell R. Factor Analysis: an Introduction and Manual for the Psychologist and Social Scientist. New York: Harper & Row; 1952.
100. Cook K, Ashton C, Byrne M, et al. A psychometric analysis of the measurement level of the rating scale, time trade-off, and standard gamble. Soc. Sci. Med. 2001;53:1275-1285.
101. Hawthorne G, Osborne RH, Elliott P. Commentary on: a psychometric analysis of the measurement level of the rating scale, standard gamble and time-trade off, by Cook et al. Soc. Sci. Med. 2003;56:895-897.
102. Brazier J, Roberts J, Tsuchiya A, et al. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 2004;13(9):873-84.
103. Kaplan R, Bush J, Berry C. The reliability, stability and generalizability of a health status index. In: Proceedings of the Social Statistics Section; 1978: American Statistical Association; 1978. p. 704-709.
104. Kaplan RM. Quality of life assessment for cost/utility studies in cancer. Cancer Treat. Rev. 1993;19 Suppl A:85-96.
105. Kaplan RM, Anderson JP, Patterson TL, et al. Validity of the Quality of Well-Being Scale for persons with human immunodeficiency virus infection. HNRC Group. HIV Neurobehavioral Research Center. Psychosom. Med. 1995;57(2):138-47.
106. Bradlyn AS, Harris CV, Warner JE, et al. An investigation of the validity of the quality of Well-Being Scale with pediatric oncology patients. Health Psychol. 1993;12(3):246-50.
107. O'Connor R. Issues in the Measurement of Health-Related Quality of Life. Melbourne: National Centre for Health Program Evaluation; 1993. Working Paper 30.
108. Visser M, Fletcher A, Parr G, et al. A comparison of three quality of life instruments in subjects with angina pectoris: the Sickness Impact Profile, the Nottingham Health Profile, and the Quality of Well Being Scale. J. Clin. Epidemiol. 1994;47(2):157-163.
109. Brazier J, Jones N, Kind P. Testing the validity of the EuroQoL and comparing it with the SF-36 health survey questionnaire. Qual. Life Res. 1993;2:169-180.
110. Andersen L, Kristiansen I, Falch J, et al. Cost-effectiveness of Alendronate for the prevention of osteoporotic fractures in Norwegian women. Working Paper. Oslo: Folkehelsa; Statens Institutt for Folkehelsa; 1995. Report No.: 11/1995.
111. Wlodarczyk JH, Brodaty H, Hawthorne G. The relationship between quality of life, Mini-Mental State Examination, and the Instrumental Activities of Daily Living in patients with Alzheimer's Disease. Arch. Gerontol. Geriatr. 2004;39(1):25-33.
112. Hogan A, Hawthorne G, Kethel L, et al. Health-related quality-of-life outcomes from adult cochlear implantation: a cross-sectional study. Cochlear Imp. Int. 2001;2(2):115-128.
113. Hawthorne G, Cheok F, Goldney R, et al. The excess cost of depression in South Australia: a comparative study of two methods of calculating burden. Aust. N. Z. J. Psychiatry 2003;37(3):362-373.
114. Goldney RD, Fisher LJ, Wilson DH, et al. Suicidal ideation and health-related quality of life in the community. Med. J. Aust. 2001;175(10):546-549.
115. Sturm JW, Osborne RH, Dewey HM, et al. Brief comprehensive quality of life assessment after stroke: the Assessment of Quality of Life instrument in the North East Melbourne Stroke Incidence study (NEMESIS). Stroke 2002;33(12):2888-94.
116. Stavem K. Reliability, validity and responsiveness of two multiattribute utility measures in patients with chronic obstructive pulmonary disease. Qual. Life Res. 1999;8(1-2):45-54.
117. Dorman P, Slattery J, Farrell B, et al. Qualitative comparison of the reliability of health status assessments with the EuroQol and SF-36 questionnaires after stroke. United Kingdom Collaborators in the International Stroke Trial. Stroke 1998;29(1):63-68.
118. van Agt HM, Essink-Bot ML, Krabbe PF, et al. Test-retest reliability of health state valuations collected with the EuroQol questionnaire. Soc. Sci. Med. 1994;39(11):1537-1544.
119. Boyle MH, Furlong W, Feeny D, et al. Reliability of the Health Utilities Index-Mark III used in the 1991 cycle 6 Canadian General Social Survey Health Questionnaire. Qual. Life Res. 1995;4:249-257.
120. Hawthorne G. The effect of different methods of collecting data: mail, telephone and filter data collection issues in utility measurement. Qual. Life Res. 2003;12:1081-1088.
121. Hawthorne G, Osborne R, McNeil H, et al. The Australian Multi-attribute Utility (AMAU): Construction and Initial Validation. Melbourne: Centre for Health Program Evaluation; 1996. Working Paper 56.
122. Hawthorne G, Richardson J, Osborne R, et al. The Assessment of Quality of Life (AQoL) Instrument: Construction, Initial Validation and Utility Scaling. Melbourne: Centre for Health Program Evaluation; 1997. Working Paper 76.
123. Araya R, Flynn T, Rojas G, et al. Cost-effectiveness of a primary care treatment program for depression in low-income women in Santiago, Chile. Am. J. Psychiatry 2006;163(8):1379-87.
124. Adams M, Kutcher S, Antoniw E, et al. Diagnostic utility of endocrine and neuroimaging screening tests in first-onset adolescent psychosis. J. Am. Acad. Child Adolesc. Psychiatry 1996;35(1):67-73.
125. Pinkerton SD, Johnson-Masotti AP, Otto-Salaj LL, et al. Cost-effectiveness of an HIV prevention intervention for mentally ill adults. Ment Health Serv Res 2001;3(1):45-55.
126. Manning W. Panel on cost-effectiveness in health and medicine recommendations: identifying costs. J. Clin. Psychiatry 1999;60(Suppl 3):54-58.
127. Noyes K, Dick AW, Holloway RG. Pramipexole v. levodopa as initial treatment for Parkinson's disease: a randomized clinical-economic trial. Med. Decis. Making 2004;24(5):472-85.
128. Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005;23(2):155-67.
129. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 2006;63(10):1079-87.
130. Holland R, Smith R, Harvey I, et al. Assessing quality of life in the elderly: a direct comparison of the EQ-5D and AQoL. Health Econ. 2004;13(8):793-805.
131. Hawthorne G. Measuring incontinence in Australia. Melbourne: Department of Psychiatry, The University of Melbourne for the Department of Health and Ageing, Australian Government, Canberra. May 2006.
132. Spitzer RL, Williams JB, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study. JAMA 1994;272(22):1749-56.
133. Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders. Results from the PRIME-MD 1000 Study. JAMA 1995;274(19): 1511-7.
134. Fayers P, Machin D. Quality of Life: Assessment, Analysis and Interpretation. Chichester: Wiley; 2000.
135. Wood J, Taylor S, Lichtman R. Social comparison in adjustment to breast cancer. J. Pers. Soc. Psychol. 1985;49:1169-1183.
136. Diener E, Suh E, Lucas R, et al. Subjective well-being: three decades of progress. Psychol. Bull. 1999;125:276-302.
137. Kring A, Kerr S, Smith D, et al. Flat affect in schizophrenia does not reflect diminished subjective experience of emotion. J. Abnorm. Psychol. 1993;102:507-517.
138. Jenkins C. Assessment of outcomes of health intervention. Soc. Sci. Med. 1992;35:367-375.
139. Awad G, Hogan T, Voruganti L, et al. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int. Clin. Psychopharmacol. 1995;10S:123-132.
140. Coucill W, Bryan S, Bentham P, et al. EQ-5D in patients with dementia: an investigation of interrater agreement. Med. Care 2001;39(8):760-71.
141. Becchi A, Rucci P, Placentino A, et al. Quality of life in patients with schizophrenia-comparison of self-report and proxy assessments. Soc. Psychiatry Psychiatr. Epidemiol. 2004;39(5):397-401.
142. Ankri J, Beaufils B, Novella JL, et al. Use of the EQ-5D among patients suffering from dementia. J. Clin. Epidemiol. 2003;56(11):1055-63.
143. Bullinger M, Azouvi P, Brooks N, et al. Quality of life in patients with traumatic brain injury-basic issues, assessment and recommendations. Restor Neurol Neurosci 2002;20(3-4):111-24.
144. Tamim H, McCusker J, Dendukuri N. Proxy reporting of quality of life using the EQ-5D. Med. Care 2002;40(12):1186-95.
145. Naglie G, Tomlinson G, Tansey C, et al. Utility-based Quality of Life measures in Alzheimer's disease. Qual. Life Res. 2006;15(4):631-43.
146. Scocco P, Fantoni G, Caon F. Role of depressive and cognitive status in self-reported evaluation of quality of life in older people: comparing proxy and physician perspectives. Age Ageing 2005;35(2):166-71.
147. Sainfort F, Becker M, Diamond R. Judgements of quality of life of individuals with severe mental disorders: patient self-report versus provider perspectives. Am. J. Psychiatry 1996;153:497-502.
148. Hawthorne G, Osborne R. Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure. Aust. N. Z. J. Public Health 2005;29(2):136-142.
149. Patterson TL, Shaw W, Semple SJ, et al. Health-related quality of life in older patients with schizophrenia and other psychoses: relationships among psychosocial and psychiatric factors. Int. J. Geriatr. Psychiatry 1997;12(4):452-61.
150. Depp CA, Davis CE, Mittal D, et al. Health-related quality of life and functioning of middle-aged and elderly adults with bipolar disorder. J. Clin. Psychiatry 2006;67(2):215-21.
151. Lonnqvist J, Sintonen H, Syvalahti E, et al. Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine. Acta Psychiatr. Scand. 1994;89(6):363-369.
152. Sapin C, Fantino B, Nowicki ML, et al. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes 2004;2:20.
153. Pyne JM, Patterson TL, Kaplan RM, et al. Assessment of the quality of life of patients with major depression. Psychiatr. Serv. 1997;48(2):224-30.
154. Kasckow JW, Twamley E, Mulchahey JJ, et al. Health-related quality of well-being in chronically hospitalized patients with schizophrenia: comparison with matched outpatients. Psychiatry Res. 2001;103(1):69-78.
155. Saarni SI, Harkanen T, Sintonen H, et al. The Impact of 29 Chronic Conditions on Healthrelated Quality of Life: A General Population Survey in Finland Using 15D and EQ-5D. Qual. Life Res. 2006; 15(9):1403-1414. 2006.
156. Goldney RD, Fisher LJ. Double depression in an Australian population. Soc. Psychiatry Psychiatr. Epidemiol. 2004;39(11):921-6.
157. Manuel DG, Schultz SE, Kopec JA. Measuring the health burden of chronic disease and injury using health adjusted life expectancy and the Health Utilities Index. J. Epidemiol. Community Health 2002;56(11):843-50.
158. Goldney R, Fisher LJ, Dal Grande E, et al. Have education and publicity about depression made a difference? A comparison of prevalence, service use and excess costs in South Australia: 1998 and 2004. Aust. N. Z. J. Psychiatry 2007:41(1);38-53.
159. Rasanen P, Roine E, Sintonen H, et al. Use of quality-adjusted life years for the estimation of effectiveness of health care: A systematic literature review. Int. J. Technol. Assess. Health Care 2006;22(2):235-41
160. PBAC. Background Document on the use of economic analysis as a basis for inclusion of pharmaceutical products on the Pharmaceutical Benefits Scheme. Canberra: Australian Government Publishing Service; 1993.
161. PBAC. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. 2nd draft. Canberra: Pharmaceutical Benefits Advisory Committee, Commonwealth of Australia; 1995.
162. Thomas S, Nay R, Moore K, et al. Continence Outcomes Measurement Suite Project (Final Report). Canberra: Australian Government, Department of Health and Ageing; 2006 April.